Design, Synthesis and In Vitro Release Studies of Co-drugs for Rheumatoid Arthritis.

Design, Synthesis and In Vitro Release Studies of Co-drugs for Rheumatoid Arthritis. Inflamm Allergy Drug Targets. 2015 Dec 1; Authors: Kashmira P, Suneela D, Shakuntalah C, Poorvashree J Abstract Rheumatoid arthritis (RA) is an autoimmune disease that results in a chronic, systemic inflammation that may affect many tissues and organs, but principally the synovial joints. The tendency for joint destruction is greatest in the early stages of disease hence current trend is to introduce a disease-modifying anti-rheumatic drug (DMARD) immediately after the diagnosis of RA in a step- up approach which is generally followed by its combination with a corticosteroid or NSAID. DMARD suppresses inflammatory activity over a long time-frame thus improving day to day function, and also prevents, lessens or delays destructive changes which may result in permanent loss of function. Hydroxychloroquine (HCQ) is a slow acting DMARD used in the early stage of RA. NSAIDs if given in combination with HCQ would provide immediate symptomatic relief from pain and inflammation even before HCQ starts showing its disease modifying effects. Long half life of HCQ results in its accumulation in the body while frequent intake of NSAID's results in severe GI side effects. Through the present project we propose to minimize these shortcomings by designing co-drugs of HCQ and NSAIDs (ibuprofen and naproxen) as a potential combination therapy for RA. Synthesis...
Source: Inflammation and Allergy Drug Targets - Category: Allergy & Immunology Authors: Tags: Inflamm Allergy Drug Targets Source Type: research